DOI: https://doi.org/10.22263/2312-4156.2019.6.8
Javadova G.Ch.1, Ioshin I.E.2, Musayev P.I.1, Guliyeva S.T.1
The role of prostaglandin analogs in the development of macular edema on their perioperative application in patients suffering from cataract with concurrent primary open-angle glaucoma
1Azerbaijan Medical University, Baku, Azerbaijan
2Federal State Budgetary Institution «Clinical Hospital», Office of the President of the Russian Federation, Moscow, Russian Federation
Vestnik VGMU. 2019;18(6):8-15.
Abstract.
Prostaglandin analogs (PGAs) are the first-line drugs used for intraocular pressure (IOP) reduction and have been widely applied in the perioperative management of the patients suffering from cataract with concurrent primary open-angle glaucoma (POAG). These drugs possess a significant hypotensive effect, are easy in use, cause few complications and work well in combination with other medicinal agents. However, being inflammation mediators, they theoretically can result in the development of postoperative cystoid macular edema (ME).
A review of the literature data shows that the evaluation of the participation of PGAs in the development of cystoid macular edema in the postoperative period after phacoemulsification by experts is not straightforward. Some specialists assert that PGAs increase the permeability of the blood-aqueous barrier, and thus can contribute to the development of cystoid ME, especially in the early postoperative period. Other experts, on the contrary, completely exclude the likelihood of any connection between the development of cystoid postoperative ME and PGAs application, explaining this by the fact that a locally used drug hardly passes into the posterior part of the eyeball and therefore cannot produce a clinically significant effect on the retina. Although much research has been performed, the answer to this question remains open up to this date.
Key words: prostaglandin analogs, cataract phacoemulsification, cystoid macular edema, primary open-angle glaucoma.
References
1. De Gregorio A, Pedrotti E, Russo L, Morselli S. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018 Jun;38(3):1129-1134. doi: http://dx.doi.org/10.1007/s10792-017-0571-x
2. Lutsenko NS, Zhaboedov DG, Molchanyuk NI, Krasnozhan OV. Features of the structure, ultrastructure of the capsule and lens epithelium with age-related cataract, combined with primary open-angle glaucoma. Oftal'mologiia Vostoch Evropa. 2018;8(2):191-7. (In Russ.)
3. Gasanov DV, Kasimov EM. Long-term results of phacocanaloplasty in case of distant pseudoexfoliation glaucoma and cataract. Vestn Oftal'mologii. 2018;134(3):28-34. (In Russ.)
4. Tanito M, Ikeda Y, Fujihara E. Effectiveness and safety of combined cataract surgery and microhook ab interno trabeculotomy in Japanese eyes with glaucoma: report of an initial case series. Jpn J Ophthalmol. 2017 Nov;61(6):457-464. doi: http://dx.doi.org/10.1007/s10384-017-0531-z
5. Marchini G, Ceruti P, Vizzari G, Berzaghi D, Zampieri A. Management of concomitant cataract and glaucoma. Dev Ophthalmol. 2017;59:155-164. doi: http://dx.doi.org/10.1159/000458494
6. Zhang ML, Hirunyachote P, Jampel H. Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma. Cochrane Database Syst Rev. 2015 Jul;(7):CD008671. doi: http://dx.doi.org/10.1002/14651858.CD008671
7. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012 Aug;38(8):1339-45. doi: http://dx.doi.org/10.1016/j.jcrs.2012.03.025
8. Petrov SYu, Antonov AA, Makarova AS, Vostrukhin SV, Safonova DM. Possibilities of prolonging the hypotensive effect of trabeculectomy. Vestn Oftal'mologii. 2015;131(1):75-81. (In Russ.)
9. Yadav KS, Sharma S. Implantable drainage devices in glaucoma: Quo vadis ? Eur J Pharm Sci. 2019 May;133:1-7. doi: http://dx.doi.org/10.1016/j.ejps.2019.03.007
10. Merkur A, Damji KF, Mintsioulis G, Hodge WG. Intraocular pressure decrease after phacoemulsification in patients with pseudoexfoliation syndrome. J Cataract Refract Surg. 2001 Apr;27(4):528-32. doi: http://dx.doi.org/10.1016/s0886-3350(00)00753-7
11. Diestelhorst M, Aspacher F, Konen W, Krieglstein GK. The effect of the flurbiprofen 0.03% eye drops on the blood-aqueous barrier in extracapsular cataract extraction with IOL implantation. Int Ophthalmol. 1991 Mar;15(2):69-73. doi: http://dx.doi.org/10.1007/bf01046423
12. Dzhashi BG, Fokin VP. Cataract surgery as a stage of treatment for primary glaucoma. Tochka zreniia Vostok – Zapad. 2015;(1):88-9. (In Russ.)
13. Tatarintseva AO. The experience of using the first Russian latanoprost 0.005% (trilactan) in the treatment of primary open-angle glaucoma. Oftal'mol Ved. 2018;11(1):67-70. (In Russ.)
14. Petrov SYu, Volzhanin AV, Kravchik MV, Mazurova YuV, Saparova LM. The effect of tafluprost on diurnal fluctuations in ophthalmotonus in primary open-angle glaucoma. Nats Zhurn Glaukoma. 2018;17(4):91-6. (In Russ.)
15. Mityaeva EN, Loskutov IA. Assessment of the state of the macular region and visual acuity in patients with glaucoma after cataract phacoemulsification. Al'm Klin Meditsiny. 2015;(36):22-5. (In Russ.)
16. Lee A, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010 Jul;4:741-64.
17. Yeh P, Ramanthan S. Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation. J Cataract Refract Surg. 2002 Oct;28(10):1814-8. doi: http://dx.doi.org/10.1016/s0886-3350(02)01334-2
18. Astakhov SYu, Tkachenko NV. Taflotan® - the first analogue of prostaglandin-F2α without a preservative: advantages in the treatment of patients with primary open-angle glaucoma. Oftal'mol Ved. 2016;9(2):59-68. (In Russ.)
19. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4594-9. doi: http://dx.doi.org/10.1167/iovs.05-0776
20. Ishibashi Т, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003 Dec;12(6):486-90. doi: http://dx.doi.org/10.1097/00061198-200312000-00008
21. Biro Z, Balla Z, Kovacs B. Change of foveal and perifoveal thickness measured by OCT after phacoemulsification and IOL implantation. Eye (Lond). 2008 Jan;22(1):8-12.
22. Furuichi M, Chiba T, Abe K, Kogure S, Iijima H, Tsukahara S, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001 Jun;10(3):233-6. doi: http://dx.doi.org/10.1097/00061198-200106000-00016
23. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996 Nov;103(11):1916-24. doi: http://dx.doi.org/10.1016/s0161-6420(96)30407-7
24. Yousufazi SY, Ye Z, Abdel-Latif AA. Prostaglandin F2 and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res.1996 Sep;63(3):305-10. doi: http://dx.doi.org/10.1006/exer.1996.0119
25. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997 Nov;124(5):683-5. doi: http://dx.doi.org/10.1016/s0002-9394(14)70907-9
26. Warwar R, Bullock J, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998 Feb;105(2):263-8. doi: http://dx.doi.org/10.1016/s0161-6420(98)92977-3
27. Ayyala RS, Cruz DA, Margo CE, Harman LE, Pautler SE, Misch DM, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998 Oct;126(4):602-4. doi: http://dx.doi.org/10.1016/s0002-9394(98)00127-5
28. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998 Jul;126(1):134-5. doi: http://dx.doi.org/10.1016/s0002-9394(98)00082-8
29. Chaudhary C, Bahadhur H, Gupta N. Study of cystoid macular edema by optical coherent tomography following uneventful cataract surgery. Int Ophthalmol. 2015 Oct;35(5):685-91. doi: http://dx.doi.org/10.1007/s10792-014-9998-5
30. Matsuura K, Sasaki S, Uotani R. Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone. Clin Ophthalmol. 2012;6:2105-8. doi: http://dx.doi.org/10.2147/OPTH.S39542
31. Ioshin IE, Tolchinskaya AI, Bagirov AM. Treatment of postoperative macular edema (clinical observation). Vestn Oftal'mologii. 2018;(3):99-107. (In Russ.)
32. Ioshin IE, Tolchinskaya AI, Kalinnikov YuYu, Ozderbaeva AA. Prevention of macular edema with cataract phacoemulsification. Ros Oftal'mol Zhurn. 2014;7(2): 21-6. (In Russ.)
33. Ioshin IE, Tolchinskaya AI. Prostaglandin analogues for cataract phacoemulsification against primary glaucoma. Klin Oftal'mologiia. 2016;16(4):185-91. (In Russ.)
34. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004 May;137(5):966-8. doi: http://dx.doi.org/10.1016/j.ajo.2003.11.068
35. Yeom HY, Hong S, Kim SS, Kim CY, Seong GJ. Influence of topical bimatoprost on macular thickness and volume in glaucoma patients with phakic eyes. Can J Ophthalmol. 2008 Oct;43(5):563-6. doi: http://dx.doi.org/10.3129/i08-092
36. Yeh P, Ramanthan S. Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation. J Cataract Refract Surg. 2002 Oct;28(10):1814-8. doi: http://dx.doi.org/10.1016/s0886-3350(02)01334-2
37. Altintaş O, Yüksel N, Karabaş VL, Demirci G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol. 2005 Jan-Feb;15(1):158-61.
38. Lima MC, Paranhos A Jr, Salim S, Honkanen R, Devgan L, Wand M, et al. Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000 Aug;9(4):317-21. doi: http://dx.doi.org/10.1097/00061198-200008000-00006
39. Basinskiy SN, Basinskiy AS, Seregina SS. The effect of prostaglandin analogues on the postoperative period in patients with glaucoma after cataract phacoemulsification. RMZh Klin Oftal'mologiia. 2014;(2):69-70. (In Russ.)
40. Alekseev IB, Samoylenko AI, Adleyba OA, Beysekeeva ZhS, Shteyner II. The effect of prostaglandin analogues on the results of cataract phacoemulsification in patients with primary open-angle glaucoma. Ros Oftal'mol Zhurn. 2012;5(2):4-7. (In Russ.)
41. Schumer R, Camras C, Mandahl A. Latanoprost and cystoidmacular edema: is there a causal relation? Curr Opin Ophthalmol. 2000 Apr;11(2):94-100.
42. Egorova GB, Fedorov AA, Averich VV. Morphological changes in glaucoma against the background of increased IOP and with prolonged hypotensive therapy according to the results of confocal microscopy of the cornea. RMZh Klin Oftal'mologiia. 2016;16(3):113-7. (In Russ.)
43. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016 Feb;123(2):316-23. doi: http://dx.doi.org/10.1016/j.ophtha.2015.10.001
Information about authors:
Javadova G.Ch. – postgraduate of the Chair of Ophthalmology, Azerbaijan Medical University, Azerbaijan;
Ioshin I.E. – Doctor of Medical Sciences, professor, head of the ophthalmologic department, Federal State Budgetary Institution «Clinical Hospital», Office of the President of the Russian Federation, Russian Federation;
Musayev P.I. – Doctor of Medical Sciences, professor, head of the Chair of Ophthalmology, Azerbaijan Medical University, Azerbaijan;
Guliyeva S.T. – Candidate of Biological Sciences, associate professor of the Chair of Pharmacology, Azerbaijan Medical University, Azerbaijan.
Correspondence address: Azerbaijan, AZ1022, Baku, 23 Bakikhanov str., Azerbaijan Medical University, Chair of Ophthalmology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Gyunesh Ch. Javadova.
